Translational Candidate H9 (WA09) embryonic stem cell-derived neural stem cells with a spinal cord identity (H9-NSCsc) Area of Impact Severe spinal cord injury Mechanism of Action Our candidate therapy for…
Therapeutic Candidate or Device Human embryonic stem cell-derived neural stem cells. Indication Spinal cord injury Therapeutic Mechanism The proposed neural stem cell therapy will be transplanted into a spinal cord…
On June 9th, 2016, Jake Javier seriously injured his spinal cord in a freak accident after diving into a swimming pool just one day before he was due to graduate…
Clinical trials are risky and rely on brave pioneers who are willing to put their bodies on the line to test something never before tried in people. At its December…
Jane Lebkowski, Asterias Biotherapeutics' VP of R&D, spoke to CIRM's governing Board about the company's CIRM-funded clinical trial for spinal cord injury. Richard Lajara, the fourth participant in a previous…
In this Google Hangout, Jane Lebkowski, PhD, president of research and development at Asterias Biotherapeutics, and Kevin Whittlesey, PhD, a CIRM science officer discuss the latest progress in stem cell-based…
Katie Sharify was one of five people with spinal cord injuries to participate in the world's first clinical trial testing human embryonic stem cells. The Geron sponsored trial was supported…
Roman Reed spoke with CIRM at the World Stem Cell Summit about what he thinks patients advocates should know about stem cell research. He came to the meeting in Pasadena…
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
